BCY LifeSciences Inc. Signs Licencing Agreement

01-Mar-2005

BCY LifeSciences Inc., (BCY) has signed an agreement with ALIGN Pharmaceuticals, Inc., (ALIGN) a private US based company, to undertake further development and the marketing of DCF 987. The compound is currently being developed for respiratory conditions, such as cystic fibrosis (CF). In 2004 BCY announced the results from a Phase II clinical study which lead to the agreement with ALIGN.

In announcing the signing of the agreement, Lorne Meikle, BCY's President & CEO commented "The agreement validates our Phase II results and means that if further clinical development is successful, patients suffering from CF and other respiratory disorders will have a new hope for managing their condition. This is truly a good news event for the patients, our partners and our shareholders."

The agreement provides for the continued development of DCF 987 with the initial focus remaining on CF. It includes industry- standard up- front and milestone payments as well as royalty payments when DCF 987 is commercialized.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances